Labcorp Holdings Inc. $LH Shares Purchased by Strs Ohio

Key Points

• Q1 beat and guidance raised: Labcorp reported EPS of $4.25 vs. $4.09 expected and revenue of $3.54B, and raised FY2026 guidance to an EPS range of $17.70–$18.35 and revenue roughly $14.7B–$14.8B.
• Significant institutional ownership and recent insider sales: Strs Ohio increased its stake by 4.9% to 86,002 shares (~$21.6M), institutional investors own about 95.9% of the stock, and insiders sold 16,113 shares (~$4.55M) over the last three months.
• Analyst outlook: Analysts collectively rate the stock a "Moderate Buy" with a consensus target price of $308, and several firms have recently raised price targets into the $300s.

Strs Ohio increased its stake in shares of Labcorp Holdings Inc. (NYSE:LH - Free Report) by 4.9% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 86,002 shares of the medical research company's stock after acquiring an additional 4,004 shares during the quarter. Strs Ohio owned about 0.10% of Labcorp worth $21,576,000 at the end of the most recent quarter.

A number of other institutional investors also recently bought and sold shares of LH. Brighton Jones LLC purchased a new position in shares of Labcorp during the fourth quarter worth about $991,000. Integrated Wealth Concepts LLC increased its position in Labcorp by 7.9% in the 1st quarter. Integrated Wealth Concepts LLC now owns 2,427 shares of the medical research company's stock valued at $565,000 after acquiring an additional 177 shares during the period. Goldman Sachs Group Inc. increased its position in Labcorp by 52.2% in the 1st quarter. Goldman Sachs Group Inc. now owns 353,843 shares of the medical research company's stock valued at $82,353,000 after acquiring an additional 121,304 shares during the period. Arrowstreet Capital Limited Partnership acquired a new position in Labcorp in the 2nd quarter valued at about $5,873,000. Finally, First Trust Advisors LP increased its position in Labcorp by 83.2% in the 2nd quarter. First Trust Advisors LP now owns 86,046 shares of the medical research company's stock valued at $22,588,000 after acquiring an additional 39,087 shares during the period. 95.94% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several equities analysts recently issued reports on LH shares. Evercore restated an "outperform" rating and issued a $300.00 price target on shares of Labcorp in a research report on Wednesday, April 8th. Wall Street Zen upgraded Labcorp from a "hold" rating to a "buy" rating in a research report on Saturday. Piper Sandler boosted their price target on Labcorp from $270.00 to $300.00 and gave the company a "neutral" rating in a research report on Tuesday, February 24th. JPMorgan Chase & Co. boosted their price target on Labcorp from $319.00 to $330.00 and gave the company an "overweight" rating in a research report on Wednesday, February 18th. Finally, Robert W. Baird set a $334.00 price target on Labcorp in a research report on Friday. Eight analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company's stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $308.00.

Insider Activity

In other news, EVP Brian J. Caveney sold 1,500 shares of the business's stock in a transaction dated Tuesday, February 24th. The shares were sold at an average price of $286.31, for a total transaction of $429,465.00. Following the transaction, the executive vice president directly owned 30,107 shares in the company, valued at $8,619,935.17. The trade was a 4.75% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, CEO Adam H. Schechter sold 8,705 shares of the business's stock in a transaction dated Tuesday, March 3rd. The stock was sold at an average price of $279.96, for a total transaction of $2,437,051.80. Following the transaction, the chief executive officer owned 80,773 shares in the company, valued at approximately $22,613,209.08. This trade represents a 9.73% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders have sold 16,113 shares of company stock valued at $4,547,450. 0.84% of the stock is owned by insiders.

Labcorp News Summary

Here are the key news stories impacting Labcorp this week:

• Positive Sentiment: Q1 results beat Street estimates — EPS of $4.25 vs. $4.09 est. and revenue of $3.54B vs. $3.51B, with revenue up ~5.8% year‑over‑year. Management pointed to broad segment growth driving the beat. Labcorp Announces 2026 First Quarter Results; Raises Full Year 2026 Guidance
• Positive Sentiment: Raised FY2026 guidance — EPS guidance range set to $17.70–$18.35 and revenue guidance roughly $14.7B–$14.8B, reflecting steady diagnostics demand that management says supports continued growth. Labcorp raises full-year forecasts on steady diagnostics demand
• Positive Sentiment: Analyst reaction was initially favorable — outlets noted pre‑market gains after the beat and the raised view, signaling positive near‑term sentiment from some desks. LH Stock Up in Pre-Market on Q1 Earnings & Revenue Beat, 2026 View Up
• Neutral Sentiment: Full earnings materials and call transcript are available for deeper review (slides, PR, and call transcript). Useful for investors who want line‑by‑line detail on margins, segment trends and cadence. Labcorp Holdings Inc. 2026 Q1 - Results - Earnings Call Presentation Labcorp Holdings Inc. (LH) Q1 2026 Earnings Call Transcript
• Neutral Sentiment: Longer‑term valuation context: coverage pieces highlight LH as a value/quality name given its margin profile and ROE, which may attract income/value investors. Here's Why Labcorp Holdings (LH) is a Strong Value Stock
• Negative Sentiment: Market reaction turned muted/negative intraday — reasons include guidance that is only modestly above consensus (company range roughly in line with Street forecasts), possible profit‑taking after the beat, and limited incremental upside in margin guidance. This helps explain why the stock is down despite the beat. Compared to Estimates, Labcorp (LH) Q1 Earnings: A Look at Key Metrics

Labcorp Trading Up 0.2%

Shares of Labcorp stock opened at $256.37 on Monday. Labcorp Holdings Inc. has a 52-week low of $239.67 and a 52-week high of $293.72. The company has a quick ratio of 1.54, a current ratio of 1.73 and a debt-to-equity ratio of 0.68. The company's 50-day simple moving average is $270.69 and its 200-day simple moving average is $267.33. The firm has a market cap of $21.07 billion, a price-to-earnings ratio of 22.71, a price-to-earnings-growth ratio of 1.72 and a beta of 0.91.

Labcorp (NYSE:LH - Get Free Report) last issued its quarterly earnings results on Thursday, April 30th. The medical research company reported $4.25 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $4.09 by $0.16. Labcorp had a net margin of 6.66% and a return on equity of 16.29%. The business had revenue of $3.54 billion for the quarter, compared to analyst estimates of $3.51 billion. During the same period in the previous year, the business posted $3.84 earnings per share. The business's revenue was up 5.8% compared to the same quarter last year. Labcorp has set its FY 2026 guidance at 17.700-18.350 EPS. As a group, equities research analysts anticipate that Labcorp Holdings Inc. will post 18 earnings per share for the current year.

Labcorp Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Thursday, June 11th. Stockholders of record on Friday, May 29th will be paid a dividend of $0.72 per share. This represents a $2.88 dividend on an annualized basis and a dividend yield of 1.1%. The ex-dividend date is Friday, May 29th. Labcorp's payout ratio is 27.53%.

Labcorp Profile

Laboratory Corporation of America Holdings, commonly known as Labcorp NYSE: LH, is a global life sciences company that provides comprehensive clinical laboratory and drug development services. The company operates a broad network of laboratories, patient service centers and specialty testing sites to deliver diagnostic information and testing solutions that support patient care, clinical decision-making and population health initiatives.

Labcorp's core businesses encompass clinical laboratory testing and pharmaceutical development services.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.